Published in Infect Immun on January 01, 2004
Reversion of the ELISPOT test after treatment in Gambian tuberculosis cases. BMC Infect Dis (2006) 2.12
Murine neonatal recent thymic emigrants are phenotypically and functionally distinct from adult recent thymic emigrants. Blood (2009) 1.95
Immunogenicity of eight dormancy regulon-encoded proteins of Mycobacterium tuberculosis in DNA-vaccinated and tuberculosis-infected mice. Infect Immun (2006) 1.63
T-cell recognition of the HspX protein of Mycobacterium tuberculosis correlates with latent M. tuberculosis infection but not with M. bovis BCG vaccination. Infect Immun (2007) 1.43
Lack of immune responses to Mycobacterium tuberculosis DosR regulon proteins following Mycobacterium bovis BCG vaccination. Infect Immun (2007) 1.33
Whole genome identification of Mycobacterium tuberculosis vaccine candidates by comprehensive data mining and bioinformatic analyses. BMC Med Genomics (2008) 1.10
DNA polymorphisms in the pepA and PPE18 genes among clinical strains of Mycobacterium tuberculosis: implications for vaccine efficacy. Infect Immun (2007) 1.05
Effects of antenatal and postnatal environments on CD4 T-cell responses to Mycobacterium bovis BCG in healthy infants in the Gambia. Clin Vaccine Immunol (2008) 1.01
In vitro cellular immune responses to complex and newly defined recombinant antigens of Mycobacterium tuberculosis. Clin Exp Immunol (2004) 0.97
Immunoproteomic identification of human T cell antigens of Mycobacterium tuberculosis that differentiate healthy contacts from tuberculosis patients. Mol Cell Proteomics (2009) 0.89
A comparative analysis of polyfunctional T cells and secreted cytokines induced by Bacille Calmette-Guérin immunisation in children and adults. PLoS One (2012) 0.89
HspX-mediated protection against tuberculosis depends on its chaperoning of a mycobacterial molecule. Immunol Cell Biol (2012) 0.88
Latency antigen α-crystallin based vaccination imparts a robust protection against TB by modulating the dynamics of pulmonary cytokines. PLoS One (2011) 0.84
Adjunctive immunotherapy with α-crystallin based DNA vaccination reduces Tuberculosis chemotherapy period in chronically infected mice. Sci Rep (2013) 0.82
Detection of natural infection with Mycobacterium intracellulare in healthy wild-caught Chacma baboons (Papio ursinus) by ESAT-6 and CFP-10 IFN-gamma ELISPOT tests following a tuberculosis outbreak. BMC Microbiol (2008) 0.77
Prime-boost vaccination strategy with bacillus Calmette-Guérin (BCG) and liposomized alpha-crystalline protein 1 reinvigorates BCG potency. Clin Exp Immunol (2015) 0.76
Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA (1999) 27.82
Variation in protection by BCG: implications of and for heterologous immunity. Lancet (1995) 9.66
Alpha-crystallin can function as a molecular chaperone. Proc Natl Acad Sci U S A (1992) 8.10
Specific immune-based diagnosis of tuberculosis. Lancet (2000) 6.81
Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat Med (2003) 5.97
A Mycobacterium tuberculosis operon encoding ESAT-6 and a novel low-molecular-mass culture filtrate protein (CFP-10). Microbiology (1998) 4.97
The tuberculin skin test. Clin Infect Dis (1993) 4.89
The efficacy of bacillus Calmette-Guérin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics (1995) 4.72
BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies. Lancet (2002) 3.75
Human cytolytic and interferon gamma-secreting CD8+ T lymphocytes specific for Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (1998) 3.59
Enumeration of T cells specific for RD1-encoded antigens suggests a high prevalence of latent Mycobacterium tuberculosis infection in healthy urban Indians. J Infect Dis (2000) 3.58
The 16-kDa alpha-crystallin (Acr) protein of Mycobacterium tuberculosis is required for growth in macrophages. Proc Natl Acad Sci U S A (1998) 3.47
Mycobacterial stationary phase induced by low oxygen tension: cell wall thickening and localization of the 16-kilodalton alpha-crystallin homolog. J Bacteriol (1998) 3.43
IL-10-producing T cells suppress immune responses in anergic tuberculosis patients. J Clin Invest (2000) 3.19
Detection of active tuberculosis infection by T cell responses to early-secreted antigenic target 6-kDa protein and culture filtrate protein 10. J Infect Dis (2000) 2.70
Patterns and implications of naturally acquired immune responses to environmental and tuberculous mycobacterial antigens in northern Malawi. J Infect Dis (2001) 2.50
The 14,000-molecular-weight antigen of Mycobacterium tuberculosis is related to the alpha-crystallin family of low-molecular-weight heat shock proteins. J Bacteriol (1992) 2.33
Antigenic equivalence of human T-cell responses to Mycobacterium tuberculosis-specific RD1-encoded protein antigens ESAT-6 and culture filtrate protein 10 and to mixtures of synthetic peptides. Infect Immun (2000) 2.29
Depressed T-cell interferon-gamma responses in pulmonary tuberculosis: analysis of underlying mechanisms and modulation with therapy. J Infect Dis (1999) 2.06
The prime-boost strategy: exciting prospects for improved vaccination. Immunol Today (2000) 2.03
Neonatal bacillus Calmette-Guérin vaccination induces adult-like IFN-gamma production by CD4+ T lymphocytes. Eur J Immunol (2001) 1.96
Molecular characterization and human T-cell responses to a member of a novel Mycobacterium tuberculosis mtb39 gene family. Infect Immun (1999) 1.95
Pathogenesis of tuberculosis in mice exposed to low and high doses of an environmental mycobacterial saprophyte before infection. Infect Immun (1997) 1.95
T cell expression cloning of a Mycobacterium tuberculosis gene encoding a protective antigen associated with the early control of infection. J Immunol (2000) 1.76
Tuberculosis contacts but not patients have higher gamma interferon responses to ESAT-6 than do community controls in The Gambia. Infect Immun (2001) 1.74
Clinical correlates of interferon gamma production in patients with tuberculosis. Clin Infect Dis (1997) 1.70
Molecular and immunological characterization of Mycobacterium tuberculosis CFP-10, an immunodiagnostic antigen missing in Mycobacterium bovis BCG. J Clin Microbiol (2000) 1.66
Active tuberculosis in Africa is associated with reduced Th1 and increased Th2 activity in vivo. Eur J Immunol (2002) 1.61
Expression cloning of an immunodominant family of Mycobacterium tuberculosis antigens using human CD4(+) T cells. J Exp Med (2000) 1.60
Cloning, expression, and immunological evaluation of two putative secreted serine protease antigens of Mycobacterium tuberculosis. Infect Immun (1999) 1.55
Classically restricted human CD8+ T lymphocytes derived from Mycobacterium tuberculosis-infected cells: definition of antigenic specificity. J Immunol (2001) 1.54
TB vaccines: progress and problems. Trends Immunol (2001) 1.50
Human T- and B-cell reactivity to the 16kDa alpha-crystallin protein of Mycobacterium tuberculosis. Scand J Immunol (1998) 1.47
Apoptosis and T cell hyporesponsiveness in pulmonary tuberculosis. J Infect Dis (1999) 1.44
Molecular cloning and immunologic reactivity of a novel low molecular mass antigen of Mycobacterium tuberculosis. J Immunol (1998) 1.38
Efficacy of Mycobacterium bovis BCG vaccination in mice undergoing prior pulmonary infection with atypical mycobacteria. Infect Immun (1984) 1.36
Investigation of environmental and host-related risk factors for tuberculosis in Africa. I. Methodological aspects of a combined design. Am J Epidemiol (2002) 1.32
Molecular cloning, expression, and immunogenicity of MTB12, a novel low-molecular-weight antigen secreted by Mycobacterium tuberculosis. Infect Immun (1998) 1.28
Vaccination with the T cell antigen Mtb 8.4 protects against challenge with Mycobacterium tuberculosis. J Immunol (2001) 1.16
Polarization of PPD-specific T-cell response of patients with tuberculosis from Th0 to Th1 profile after successful antimycobacterial therapy or in vitro conditioning with interferon-alpha or interleukin-12. Am J Respir Cell Mol Biol (2001) 1.12
Uncommon presentations of tuberculosis: the potential value of a novel diagnostic assay based on the Mycobacterium tuberculosis-specific antigens ESAT-6 and CFP-10. Int J Tuberc Lung Dis (2001) 1.10
Specificity of tuberculins and antigens from various species of mycobacteria. Am Rev Respir Dis (1970) 1.00
Predictive value of interferon-γ release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis (2011) 5.34
Evaluation of tuberculosis diagnostics in children: 1. Proposed clinical case definitions for classification of intrathoracic tuberculosis disease. Consensus from an expert panel. J Infect Dis (2012) 4.60
Effect of household and community interventions on the burden of tuberculosis in southern Africa: the ZAMSTAR community-randomised trial. Lancet (2013) 4.58
A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. Nat Genet (2007) 4.23
Role of flies and provision of latrines in trachoma control: cluster-randomised controlled trial. Lancet (2004) 3.69
How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J Infect Dis (2004) 3.50
CISH and susceptibility to infectious diseases. N Engl J Med (2010) 3.31
Human immunodeficiency virus and the prevalence of undiagnosed tuberculosis in African gold miners. Am J Respir Crit Care Med (2004) 3.26
Immune activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection. PLoS Biol (2004) 3.20
Progression to active tuberculosis, but not transmission, varies by Mycobacterium tuberculosis lineage in The Gambia. J Infect Dis (2008) 3.15
Innovative trial designs are practical solutions for improving the treatment of tuberculosis. J Infect Dis (2012) 3.09
Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis. PLoS Med (2009) 3.05
A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease. Nat Med (2004) 2.93
Scaling up interventions to achieve global tuberculosis control: progress and new developments. Lancet (2012) 2.83
Is operational research delivering the goods? The journey to success in low-income countries. Lancet Infect Dis (2012) 2.62
Large-scale evaluation of enzyme-linked immunospot assay and skin test for diagnosis of Mycobacterium tuberculosis infection against a gradient of exposure in The Gambia. Clin Infect Dis (2004) 2.62
Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immunol (2004) 2.56
A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med (2014) 2.39
Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Vaccine (2005) 2.31
Global tuberculosis drug development pipeline: the need and the reality. Lancet (2010) 2.26
Pattern and diversity of cytokine production differentiates between Mycobacterium tuberculosis infection and disease. Eur J Immunol (2009) 2.16
Effectiveness of a strategy to improve adherence to tuberculosis treatment in a resource-poor setting: a cluster randomized controlled trial. JAMA (2007) 2.13
Reversion of the ELISPOT test after treatment in Gambian tuberculosis cases. BMC Infect Dis (2006) 2.12
Influence of Mycobacterium bovis bacillus Calmette-Guérin on antibody and cytokine responses to human neonatal vaccination. J Immunol (2002) 1.98
"That is why I stopped the ART": patients' & providers' perspectives on barriers to and enablers of HIV treatment adherence in a South African workplace programme. BMC Public Health (2008) 1.96
Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis. PLoS Med (2009) 1.95
The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs. Infect Immun (2004) 1.90
Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys. Proc Natl Acad Sci U S A (2009) 1.86
Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon. Infect Immun (2007) 1.85
Mature CD8(+) T lymphocyte response to viral infection during fetal life. J Clin Invest (2003) 1.85
Risk factors for positive tuberculin skin test in Guinea-Bissau. Epidemiology (2007) 1.78
Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis. Tuberculosis (Edinb) (2005) 1.73
Risk factors for tuberculosis infection in sub-Saharan Africa: a contact study in The Gambia. Am J Respir Crit Care Med (2003) 1.73
Quantitative T cell assay reflects infectious load of Mycobacterium tuberculosis in an endemic case contact model. Clin Infect Dis (2004) 1.71
Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa. Antivir Ther (2009) 1.66
Active tuberculosis in Africa is associated with reduced Th1 and increased Th2 activity in vivo. Eur J Immunol (2002) 1.61
The risk and timing of tuberculosis diagnosed in smear-negative TB suspects: a 12 month cohort study in Harare, Zimbabwe. PLoS One (2010) 1.60
Comparison of enzyme-linked immunospot assay and tuberculin skin test in healthy children exposed to Mycobacterium tuberculosis. Pediatrics (2006) 1.56
Mycobacterium africanum elicits an attenuated T cell response to early secreted antigenic target, 6 kDa, in patients with tuberculosis and their household contacts. J Infect Dis (2006) 1.56
Risk factors for pulmonary tuberculosis: a clinic-based case control study in The Gambia. BMC Public Health (2006) 1.55
Use of multiepitope polyproteins in serodiagnosis of active tuberculosis. Clin Diagn Lab Immunol (2002) 1.54
Evaluation of a workplace HIV treatment programme in South Africa. AIDS (2007) 1.52
Efficacy of secondary isoniazid preventive therapy among HIV-infected Southern Africans: time to change policy? AIDS (2003) 1.51
Mycobacterium tuberculosis-specific CD8+ T cells preferentially recognize heavily infected cells. Am J Respir Crit Care Med (2003) 1.51
High incidence of invasive group B streptococcal infections in HIV-exposed uninfected infants. Pediatrics (2010) 1.47
Polyfunctional CD4(+) and CD8(+) T cell responses to tuberculosis antigens in HIV-1-infected patients before and after anti-retroviral treatment. J Immunol (2010) 1.45
Expanded polyfunctional T cell response to mycobacterial antigens in TB disease and contraction post-treatment. PLoS One (2010) 1.44
Vitamin D receptor polymorphisms and susceptibility to tuberculosis in West Africa: a case-control and family study. J Infect Dis (2004) 1.43
Interleukin-10, polymorphism in SLC11A1 (formerly NRAMP1), and susceptibility to tuberculosis. J Infect Dis (2002) 1.42
Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis. Infect Immun (2002) 1.42
Delaying bacillus Calmette-Guérin vaccination from birth to 4 1/2 months of age reduces postvaccination Th1 and IL-17 responses but leads to comparable mycobacterial responses at 9 months of age. J Immunol (2010) 1.42
Diagnostic accuracy of a urine lipoarabinomannan enzyme-linked immunosorbent assay for screening ambulatory HIV-infected persons for tuberculosis. J Acquir Immune Defic Syndr (2011) 1.41
Sensitivity of IFN-gamma release assay to detect latent tuberculosis infection is retained in HIV-infected patients but dependent on HIV/AIDS progression. PLoS One (2008) 1.40
Human cytomegalovirus elicits fetal gammadelta T cell responses in utero. J Exp Med (2010) 1.39
Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for action. Lancet Infect Dis (2013) 1.39
Undiagnosed tuberculosis among HIV clinic attendees: association with antiretroviral therapy and implications for intensified case finding, isoniazid preventive therapy, and infection control. J Acquir Immune Defic Syndr (2012) 1.39
Evaluation of the prognostic value of IFN-gamma release assay and tuberculin skin test in household contacts of infectious tuberculosis cases in Senegal. PLoS One (2010) 1.37
An evaluation of culture results during treatment for tuberculosis as surrogate endpoints for treatment failure and relapse. PLoS One (2013) 1.36
The relationship of acceptance or denial of HIV-status to antiretroviral adherence among adult HIV patients in urban Botswana. Soc Sci Med (2008) 1.36
Stable incidence rates of tuberculosis (TB) among human immunodeficiency virus (HIV)-negative South African gold miners during a decade of epidemic HIV-associated TB. J Infect Dis (2003) 1.36
Safety and immunogenicty of RTS,S/AS02A candidate malaria vaccine in Gambian children. Vaccine (2005) 1.35
An inclusion membrane protein from Chlamydia trachomatis enters the MHC class I pathway and stimulates a CD8+ T cell response. J Immunol (2003) 1.34
Uninfected but not unaffected: chronic maternal infections during pregnancy, fetal immunity, and susceptibility to postnatal infections. Lancet Infect Dis (2012) 1.33
Risk factors for and clinical outcome of congenital cytomegalovirus infection in a peri-urban West-African birth cohort. PLoS One (2007) 1.33
rBCG induces strong antigen-specific T cell responses in rhesus macaques in a prime-boost setting with an adenovirus 35 tuberculosis vaccine vector. PLoS One (2008) 1.31
Low haemoglobin predicts early mortality among adults starting antiretroviral therapy in an HIV care programme in South Africa: a cohort study. BMC Public Health (2010) 1.30
Polymorphism within the interferon-gamma/receptor complex is associated with pulmonary tuberculosis. Am J Respir Crit Care Med (2006) 1.29
Sex differences in the vaccine-specific and non-targeted effects of vaccines. Vaccine (2011) 1.27
Tracking antigen-specific CD8 T lymphocytes in the lungs of mice vaccinated with the Mtb72F polyprotein. Infect Immun (2005) 1.26
Cytomegalovirus infection in Gambian infants leads to profound CD8 T-cell differentiation. J Virol (2007) 1.26
Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa. PLoS One (2008) 1.25
Interferon regulatory factor 7-mediated responses are defective in cord blood plasmacytoid dendritic cells. Eur J Immunol (2008) 1.24
Stroke presentation and outcome in developing countries: a prospective study in the Gambia. Stroke (2005) 1.24
Secreted proteins from Mycobacterium tuberculosis gain access to the cytosolic MHC class-I antigen-processing pathway. J Immunol (2006) 1.24
Evaluation of the Mtb72F polyprotein vaccine in a rabbit model of tuberculous meningitis. Infect Immun (2006) 1.23
Association of a polymorphism in the P2X7 gene with tuberculosis in a Gambian population. J Infect Dis (2002) 1.23
Screening for tuberculosis among 2381 household contacts of sputum-smear-positive cases in The Gambia. Trans R Soc Trop Med Hyg (2007) 1.22
Priorities for tuberculosis research: a systematic review. Lancet Infect Dis (2010) 1.22